Insider Trading activities of Anacor Pharmaceuticals Inc insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Anacor Pharmaceuticals Inc since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Anacor Pharmaceuticals Inc since year 2005. Table 2 shows the detailed insider transactions of Anacor Pharmaceuticals Inc since 2005. The reporting company's ticker symbol is ANAC. The reporting company's CIK number is 1411158.
The total value of stock buying since 2005 is $39,673,266.
The total value of stock sales since 2005 is $252,302,650.
The total value of stock option exercises since 2005 is $5,460,637.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Anacor Pharmaceuticals Inc (ANAC).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2016-06 0 $0 751 $74,559 0 $0
2016-05 0 $0 362,881 $36,160,480 9,000 $127,980
2016-04 0 $0 232,426 $16,895,587 0 $0
2016-03 0 $0 46,500 $2,829,976 89,000 $679,782
2016-01 0 $0 25,587 $2,503,736 31,800 $488,290
2015-12 0 $0 1,004,000 $112,013,406 64,000 $894,560
2015-11 0 $0 100,295 $10,390,562 0 $0
2015-09 0 $0 34,000 $4,754,538 34,000 $181,360
2015-08 0 $0 20,000 $2,759,300 20,000 $102,200
2015-06 0 $0 12,600 $871,113 12,000 $75,060
2015-05 0 $0 77,522 $4,857,904 62,002 $630,658
2015-04 0 $0 62,645 $3,942,230 0 $0
2015-03 3,000 $157,305 79,895 $4,229,377 17,000 $120,040
2015-02 0 $0 7,475 $279,228 0 $0
2015-01 0 $0 7,475 $239,792 0 $0
2014-12 0 $0 387,060 $13,559,662 187,285 $1,290,955
2014-11 0 $0 12,475 $394,018 5,000 $36,250
2014-10 0 $0 7,475 $182,542 0 $0
2014-09 6,590 $143,809 900,754 $22,345,646 42,185 $258,383
2014-08 0 $0 23,901 $510,520 11,253 $79,727
2014-06 0 $0 1,620 $23,796 0 $0
2014-05 0 $0 1,500 $21,231 0 $0
2014-04 0 $0 1,500 $23,397 0 $0
2014-03 7,410 $155,003 148,000 $3,072,897 0 $0
2014-02 0 $0 18,000 $312,985 0 $0
2014-01 0 $0 68,000 $1,121,783 44,600 $26,760
2013-12 0 $0 43,328 $706,042 285,480 $171,288
2013-11 20,000 $262,430 300,000 $4,218,000 34,782 $225,735
2013-08 50,000 $417,199 1,052 $10,225 0 $0
2013-06 43,046 $224,334 5,600 $30,189 0 $0
2013-04 0 $0 25,000 $200,250 0 $0
2013-03 0 $0 20,000 $138,200 0 $0
2012-12 0 $0 0 $0 20,000 $12,000
2012-11 0 $0 6,000 $33,096 0 $0
2012-10 0 $0 44,400 $294,307 0 $0
2012-09 0 $0 276,950 $1,794,797 0 $0
2012-08 5,000 $30,955 3,000 $18,498 0 $0
2012-07 0 $0 3,000 $18,087 0 $0
2012-06 7,954 $38,294 3,000 $16,320 0 $0
2012-05 0 $0 3,000 $16,025 0 $0
2012-04 0 $0 3,000 $16,389 0 $0
2012-03 10,000 $60,817 3,000 $19,341 0 $0
2012-02 0 $0 3,000 $17,694 0 $0
2012-01 0 $0 6,000 $37,794 0 $0
2011-12 0 $0 16,000 $98,313 0 $0
2011-11 0 $0 4,000 $19,632 0 $0
2011-10 0 $0 4,000 $26,592 0 $0
2011-09 0 $0 4,000 $20,892 0 $0
2011-08 0 $0 4,000 $19,268 0 $0
2011-07 0 $0 4,000 $24,656 0 $0
2011-06 0 $0 14,000 $85,871 15,000 $9,000
2011-05 30,000 $183,120 8,368 $51,907 96,020 $50,609
2010-11 7,600,000 $38,000,000 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Anacor Pharmaceuticals Inc insiders (ANAC)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2016-06-01 Bell Graeme (Executive VP and CFO) Sale 751 99.28 74,559
2016-05-23 Leonard Keith R (Director) Sale 9,000 99.70 897,300
2016-05-23 Leonard Keith R (Director) Option Ex 9,000 14.22 127,980
2016-05-16 Hove Anders D (Director) Sale 353,881 99.65 35,263,180
2016-04-29 Sullivan Ryan T (EVP and General Counsel) Sale 3,125 66.33 207,281
2016-04-08 Hove Anders D (Director) Sale 4,268 70.72 301,854
2016-04-07 Hove Anders D (Director) Sale 225,033 72.82 16,386,452
2016-03-31 Rieflin William Jl (Director) Option Ex 89,000 7.64 679,782
2016-03-22 Berns Paul L (President and CEO) Sale 37,500 60.17 2,256,487
2016-03-02 Ippolito Vincent P (EVP & Chief Commercial Officer) Sale 9,000 63.72 573,489
2016-01-22 Zane Lee (SVP and Chief Medical Officer) Option Ex 11,800 7.55 89,090
2016-01-19 Ippolito Vincent P (EVP & Chief Commercial Officer) Sale 20,000 95.54 1,910,780
2016-01-19 Ippolito Vincent P (EVP & Chief Commercial Officer) Option Ex 20,000 19.96 399,200
2016-01-15 Zane Lee (SVP and Chief Medical Officer) Sale 1,466 89.57 131,309
2016-01-04 Sullivan Ryan T (Sr. VP and General Counsel) Sale 733 111.72 81,892
2016-01-04 Ippolito Vincent P (EVP & Chief Commercial Officer) Sale 855 112.07 95,819
2016-01-04 Berns Paul L (President and CEO) Sale 2,533 112.10 283,936
2015-12-15 Zane Lee (SVP and Chief Medical Officer) Sale 14,000 113.49 1,588,916
2015-12-15 Zane Lee (SVP and Chief Medical Officer) Option Ex 14,000 5.59 78,260
2015-12-15 Hove Anders D (Director) Sale 900,000 111.25 100,125,000
2015-12-11 Hove Anders D (Director) Sale 40,000 117.36 4,694,400
2015-12-11 Berns Paul L (President and CEO) Sale 20,000 117.19 2,343,760
2015-12-11 Berns Paul L (President and CEO) Option Ex 20,000 13.20 264,100
2015-12-10 Sullivan Ryan T (Sr. VP and General Counsel) Sale 10,000 110.06 1,100,590
2015-12-10 Sullivan Ryan T (Sr. VP and General Counsel) Option Ex 10,000 15.30 153,000
2015-12-09 Ippolito Vincent P (EVP & Chief Commercial Officer) Sale 20,000 108.04 2,160,740
2015-12-09 Ippolito Vincent P (EVP & Chief Commercial Officer) Option Ex 20,000 19.96 399,200
2015-11-10 Hove Anders D (Director) Sale 100,295 103.60 10,390,562
2015-09-15 Zane Lee (SVP and Chief Medical Officer) Sale 14,000 139.85 1,957,858
2015-09-15 Zane Lee (SVP and Chief Medical Officer) Option Ex 14,000 5.59 78,260
2015-09-15 Berns Paul L (President and CEO) Sale 20,000 139.83 2,796,680
2015-09-15 Berns Paul L (President and CEO) Option Ex 20,000 5.16 103,100
2015-08-13 Berns Paul L (President and CEO) Sale 20,000 137.96 2,759,300
2015-08-13 Berns Paul L (President and CEO) Option Ex 20,000 5.11 102,200
2015-06-15 Zane Lee (SVP and Chief Medical Officer) Sale 12,000 69.05 828,588
2015-06-15 Zane Lee (SVP and Chief Medical Officer) Option Ex 12,000 6.26 75,060
2015-06-01 Maples Kirk R (SVP, Program Management) Sale 600 70.88 42,525
2015-05-15 Plattner Jacob J (Senior VP, Research) Sale 8,920 63.73 568,471
2015-05-14 Rodriguez Carmen R (Snr VP Reg Afrs & Qual. Assur.) Sale 6,000 63.76 382,554
2015-05-13 Rodriguez Carmen R (Snr VP Reg Afrs & Qual. Assur.) Sale 41,768 62.83 2,624,116
2015-05-13 Rodriguez Carmen R (Snr VP Reg Afrs & Qual. Assur.) Option Ex 41,768 11.74 490,356
2015-05-12 Rodriguez Carmen R (Snr VP Reg Afrs & Qual. Assur.) Sale 14,174 62.05 879,553
2015-05-12 Rodriguez Carmen R (Snr VP Reg Afrs & Qual. Assur.) Option Ex 14,174 6.94 98,367
2015-05-12 Maples Kirk R (SVP, Program Management) Sale 6,060 61.23 371,071
2015-05-12 Maples Kirk R (SVP, Program Management) Option Ex 6,060 6.92 41,935
2015-05-01 Maples Kirk R (SVP, Program Management) Sale 600 53.57 32,139
2015-04-29 Sullivan Ryan T (Sr. VP and General Counsel) Sale 3,125 53.61 167,531
2015-04-27 Berns Paul L (President and CEO) Sale 25,000 61.71 1,542,650
2015-04-24 Berns Paul L (President and CEO) Sale 25,000 65.50 1,637,575
2015-04-15 Plattner Jacob J (Senior VP, Research) Sale 8,920 62.81 560,265
2015-04-01 Maples Kirk R (SVP, Program Management) Sale 600 57.02 34,209
2015-03-23 Parker Geoffrey M. (Executive Vice President & CFO) Buy 3,000 52.44 157,305
2015-03-19 Berns Paul L (President and CEO) Sale 37,500 56.07 2,102,662
2015-03-16 Zane Lee (SVP and Chief Medical Officer) Sale 12,000 56.51 678,156
2015-03-16 Zane Lee (SVP and Chief Medical Officer) Option Ex 12,000 6.92 83,040
2015-03-16 Plattner Jacob J (Senior VP, Research) Sale 8,920 55.60 495,952
2015-03-04 Chanda Sanjay (SVP, Drug Development) Sale 5,000 45.00 225,000
2015-03-04 Chanda Sanjay (SVP, Drug Development) Option Ex 5,000 7.40 37,000
2015-03-03 Ippolito Vincent P (EVP & Chief Commercial Officer) Sale 9,000 44.08 396,711
2015-03-02 Maples Kirk R (SVP, Program Management) Sale 600 43.95 26,368
2015-03-02 Plattner Jacob J (Senior VP, Research) Sale 6,875 44.30 304,528
2015-02-02 Maples Kirk R (SVP, Program Management) Sale 600 37.41 22,447
2015-02-02 Plattner Jacob J (Senior VP, Research) Sale 6,875 37.35 256,781
2015-01-02 Maples Kirk R (SVP, Program Management) Sale 600 31.96 19,174
2015-01-02 Plattner Jacob J (Senior VP, Research) Sale 6,875 32.09 220,618
2014-12-29 Zane Lee (SVP and Chief Medical Officer) Option Ex 14,291 6.50 92,891
2014-12-26 Berns Paul L (President and CEO) Sale 25,000 30.82 770,500
2014-12-19 Chanda Sanjay (SVP, Drug Development) Option Ex 19,073 6.26 119,301
2014-12-12 Shapiro Lucy (Director) Sale 49,831 34.46 1,717,325
2014-12-11 Zane Lee (SVP and Chief Medical Officer) Sale 100 36.00 3,600
2014-12-11 Zane Lee (SVP and Chief Medical Officer) Option Ex 100 5.00 500
2014-12-11 Shapiro Lucy (Director) Sale 150,833 34.92 5,266,334
2014-12-10 Zane Lee (SVP and Chief Medical Officer) Sale 4,800 36.09 173,251
2014-12-10 Zane Lee (SVP and Chief Medical Officer) Option Ex 4,800 5.00 24,000
2014-12-10 Shapiro Lucy (Director) Sale 89,021 35.79 3,185,705
2014-12-10 Shapiro Lucy (Director) Option Ex 89,021 7.63 678,963
2014-12-09 Maples Kirk R (SVP, Program Management) Sale 60,000 36.52 2,191,380
2014-12-09 Maples Kirk R (SVP, Program Management) Option Ex 60,000 6.26 375,300
2014-12-01 Maples Kirk R (SVP, Program Management) Sale 600 33.64 20,182
2014-12-01 Plattner Jacob J (Senior VP, Research) Sale 6,875 33.66 231,385
2014-11-26 Chanda Sanjay (SVP, Drug Development) Sale 5,000 35.00 175,000
2014-11-26 Chanda Sanjay (SVP, Drug Development) Option Ex 5,000 7.25 36,250
2014-11-03 Maples Kirk R (SVP, Program Management) Sale 600 29.10 17,457
2014-11-03 Plattner Jacob J (Senior VP, Research) Sale 6,875 29.32 201,561
2014-10-01 Maples Kirk R (SVP, Program Management) Sale 600 23.85 14,311
2014-10-01 Plattner Jacob J (Senior VP, Research) Sale 6,875 24.47 168,231
2014-09-26 Hove Anders D (Director) Sale 20,000 25.00 500,000
2014-09-19 Hove Anders D (Director) Sale 738,500 24.87 18,366,495
2014-09-18 Hove Anders D (Director) Sale 1,500 24.87 37,305
2014-09-16 Hove Anders D (Director) Sale 75,000 24.99 1,874,249
2014-09-12 Hove Anders D (Director) Sale 15,000 24.98 374,700
2014-09-10 Chanda Sanjay (SVP, Drug Development) Sale 10,000 24.25 242,500
2014-09-10 Chanda Sanjay (SVP, Drug Development) Option Ex 10,000 6.12 61,250
2014-09-08 Parker Geoffrey M. (Executive Vice President & CFO) Buy 1,229 22.05 27,095
2014-09-05 Parker Geoffrey M. (Executive Vice President & CFO) Buy 5,361 21.77 116,714
2014-09-02 Maples Kirk R (SVP, Program Management) Sale 33,879 23.32 789,956
2014-09-02 Maples Kirk R (SVP, Program Management) Option Ex 32,185 6.12 197,133
2014-09-02 Plattner Jacob J (Senior VP, Research) Sale 6,875 23.34 160,441
2014-08-27 Leschly Mark (Director) Sale 13,067 22.50 294,007
2014-08-13 Maples Kirk R (SVP, Program Management) Sale 3,959 19.96 79,013
2014-08-13 Maples Kirk R (SVP, Program Management) Option Ex 11,253 7.08 79,727
2014-08-13 Plattner Jacob J (Senior VP, Research) Sale 6,875 20.00 137,500
2014-06-04 Maples Kirk R (SVP, Program Management) Sale 1,620 14.69 23,796
2014-05-20 Maples Kirk R (SVP, Program Management) Sale 1,500 14.15 21,231
2014-04-21 Maples Kirk R (SVP, Program Management) Sale 1,500 15.60 23,397
2014-03-24 Parker Geoffrey M. (Senior Vice President and CFO) Buy 5,000 20.11 100,535
2014-03-21 Shapiro Lucy (Director) Sale 80,000 21.14 1,691,360
2014-03-20 Maples Kirk R (SVP, Program Management) Sale 3,000 22.53 67,590
2014-03-18 Parker Geoffrey M. (Senior Vice President and CFO) Buy 2,410 22.60 54,468
2014-03-05 Perry David P (President and CEO) Sale 7,500 20.24 151,815
2014-03-04 Perry David P (President and CEO) Sale 57,500 20.21 1,162,132
2014-02-20 Maples Kirk R (SVP, Program Management) Sale 3,000 19.33 57,978
2014-02-05 Perry David P (President and CEO) Sale 7,500 16.71 125,302
2014-02-04 Perry David P (President and CEO) Sale 7,500 17.29 129,705
2014-01-27 Plattner Jacob J (Senior VP, Research) Option Ex 44,600 .60 26,760
2014-01-21 Maples Kirk R (SVP, Program Management) Sale 3,000 20.28 60,824
2014-01-09 Perry David P (President and CEO) Sale 7,500 16.49 123,652
2014-01-08 Perry David P (President and CEO) Sale 57,500 16.30 937,307
2013-12-20 Maples Kirk R (SVP, Program Management) Sale 3,000 16.73 50,178
2013-12-09 Perry David P (President and CEO) Sale 10,328 16.72 172,715
2013-12-09 Perry David P (President and CEO) Option Ex 285,480 .60 171,288
2013-12-06 Perry David P (President and CEO) Sale 15,000 16.78 251,759
2013-12-05 Perry David P (President and CEO) Sale 15,000 15.43 231,390
2013-11-26 Parker Geoffrey M. (Senior Vice President and CFO) Buy 10,000 13.40 133,950
2013-11-25 Maples Kirk R (SVP, Program Management) Option Ex 34,782 6.49 225,735
2013-11-25 Parker Geoffrey M. (Senior Vice President and CFO) Buy 10,000 12.85 128,480
2013-11-15 Hove Anders D (Director) Sale 150,000 14.06 2,109,000
2013-11-15 Roberts Bryan E (10% Owner) Sale 150,000 14.06 2,109,000
2013-08-14 Maples Kirk R (SVP, Program Management) Sale 1,052 9.72 10,225
2013-08-13 Parker Geoffrey M. (Senior Vice President and CFO) Buy 50,000 8.34 417,199
2013-06-19 Parker Geoffrey M. (Senior Vice President and CFO) Buy 23,046 5.20 119,954
2013-06-18 Parker Geoffrey M. (Senior Vice President and CFO) Buy 20,000 5.22 104,380
2013-06-14 Maples Kirk R (SVP, Program Management) Sale 5,600 5.39 30,189
2013-04-19 Shapiro Lucy (Director) Sale 25,000 8.01 200,250
2013-03-22 Shapiro Lucy (Director) Sale 20,000 6.91 138,200
2012-12-06 Plattner Jacob J (Senior VP, Research) Option Ex 20,000 .60 12,000
2012-11-26 Maples Kirk R (SVP, Program Management) Sale 3,000 5.22 15,666
2012-11-01 Maples Kirk R (SVP, Program Management) Sale 3,000 5.81 17,430
2012-10-05 Shapiro Lucy (Director) Sale 15,000 6.66 99,900
2012-10-03 Shapiro Lucy (Director) Sale 15,000 6.68 100,275
2012-10-01 Shapiro Lucy (Director) Sale 14,400 6.54 94,132
2012-09-28 Shapiro Lucy (Director) Sale 5,600 6.65 37,223
2012-09-26 Shapiro Lucy (Director) Sale 10,000 6.58 65,800
2012-09-24 Maples Kirk R (SVP, Program Management) Sale 3,000 6.56 19,665
2012-09-24 Shapiro Lucy (Director) Sale 10,000 6.35 63,540
2012-09-21 Shapiro Lucy (Director) Sale 10,000 6.30 62,960
2012-09-20 Vhcp Management, Llc (10% Owner) Sale 19,273 6.30 121,458
2012-09-20 Hove Anders D (Director) Sale 19,273 6.30 121,458
2012-09-20 Roberts Bryan E (10% Owner) Sale 19,273 6.30 121,458
2012-09-14 Vhcp Management, Llc (10% Owner) Sale 35,000 6.51 227,815
2012-09-14 Hove Anders D (Director) Sale 35,000 6.51 227,815
2012-09-14 Roberts Bryan E (10% Owner) Sale 35,000 6.51 227,815
2012-09-13 Vhcp Management, Llc (10% Owner) Sale 15,000 6.56 98,325
2012-09-13 Hove Anders D (Director) Sale 15,000 6.56 98,325
2012-09-13 Roberts Bryan E (10% Owner) Sale 15,000 6.56 98,325
2012-09-11 Vhcp Management, Llc (10% Owner) Sale 10,177 6.64 67,605
2012-09-11 Hove Anders D (Director) Sale 10,177 6.64 67,605
2012-09-11 Roberts Bryan E (10% Owner) Sale 10,177 6.64 67,605
2012-08-27 Maples Kirk R (SVP, Program Management) Sale 3,000 6.17 18,498
2012-08-22 Parker Geoffrey M. (Senior Vice President and CFO) Buy 5,000 6.19 30,955
2012-07-30 Maples Kirk R (SVP, Program Management) Sale 3,000 6.03 18,087
2012-06-25 Maples Kirk R (SVP, Program Management) Sale 3,000 5.44 16,320
2012-06-05 Parker Geoffrey M. (Senior Vice President and CFO) Buy 4,314 4.93 21,259
2012-06-04 Parker Geoffrey M. (Senior Vice President and CFO) Buy 3,640 4.68 17,035
2012-05-29 Maples Kirk R (SVP, Program Management) Sale 3,000 5.34 16,025
2012-04-23 Maples Kirk R (SVP, Program Management) Sale 3,000 5.46 16,389
2012-03-26 Maples Kirk R (SVP, Program Management) Sale 3,000 6.45 19,341
2012-03-20 Parker Geoffrey M. (Senior Vice President and CFO) Buy 9,400 6.08 57,199
2012-03-19 Parker Geoffrey M. (Senior Vice President and CFO) Buy 600 6.03 3,618
2012-02-27 Maples Kirk R (SVP, Program Management) Sale 3,000 5.90 17,694
2012-01-30 Maples Kirk R (SVP, Program Management) Sale 3,000 7.11 21,342
2012-01-10 Maples Kirk R (SVP, Program Management) Sale 3,000 5.48 16,452
2011-12-30 Maples Kirk R (S.V.P., Program Management) Sale 10,000 6.14 61,449
2011-12-29 Maples Kirk R (SVP Program Management) Sale 6,000 6.14 36,864
2011-11-28 Maples Kirk R (S.V.P., Program Management) Sale 4,000 4.91 19,632
2011-10-31 Maples Kirk R (SVP Program Management) Sale 4,000 6.65 26,592
2011-09-26 Maples Kirk R (S.V.P., Program Management) Sale 4,000 5.22 20,892
2011-08-29 Maples Kirk R (S.V.P., Program Management) Sale 4,000 4.82 19,268
2011-07-25 Maples Kirk R (SVP, Program Management) Sale 4,000 6.16 24,656
2011-06-27 Maples Kirk R (SVP, Program Management) Sale 4,000 6.40 25,596
2011-06-06 Maples Kirk R (SVP, Program Management) Sale 5,000 6.06 30,275
2011-06-03 Plattner Jacob J (Senior VP, Research) Option Ex 15,000 .60 9,000
2011-06-01 Maples Kirk R (SVP, Program Management) Sale 5,000 6.00 30,000
2011-05-25 Maples Kirk R (SVP, Program Management) Sale 3,776 6.45 24,355
2011-05-25 Maples Kirk R (SVP, Program Management) Option Ex 40,000 .60 24,000
2011-05-24 Maples Kirk R (SVP, Program Management) Sale 4,592 6.00 27,552
2011-05-24 Maples Kirk R (SVP, Program Management) Option Ex 56,020 .48 26,609
2011-05-24 Parker Geoffrey M. (Sr. V.P. & CFO) Buy 5,000 5.92 29,600
2011-05-23 Parker Geoffrey M. (Sr. V.P. & CFO) Buy 5,000 6.00 30,000
2011-05-10 Parker Geoffrey M. (Senior Vice President and CFO) Buy 20,000 6.18 123,520
2010-11-30 Aberdare Gp Ii, L.l.c. (10% Owner) Buy 300,000 5.00 1,500,000
2010-11-30 Hove Anders D (Director) Buy 600,000 5.00 3,000,000
2010-11-30 Vef Management Iv, Llc (10% Owner) Buy 600,000 5.00 3,000,000
2010-11-30 Leschly Mark (Director) Buy 2,400,000 5.00 12,000,000
2010-11-30 Ruch Joshua Buy 2,400,000 5.00 12,000,000
2010-11-30 Klingenstein Paul H (Director) Buy 300,000 5.00 1,500,000
2010-11-24 Glaxosmithkline Plc (10% Owner) Buy 1,000,000 5.00 5,000,000

Insider trading activities including stock purchases, stock sales, and option exercises of ANAC listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Anacor Pharmaceuticals Inc (symbol ANAC, CIK number 1411158) see the Securities and Exchange Commission (SEC) website.